[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-leukemia-acute-lymphoblastic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-leukemia-acute-lymphoblastic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,76,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604632","phase-3-newly-diagnosed-pediatric-ph-positive-b-all-protocol-100604632",false,"NCT07152041","Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","A Phase 3, Multicenter Trial for Pediatric Philadelphia Chromosome-positive B-Acute Lymphoblastic Leukemia -2025 Project","CAMS-Ph+ B-ALL","Inclusion Criteria:\n\nMust meet all items below:\n\n1. Age older than 1 month to younger 18 years.\n2. Newly diagnosed Philadelphia chromosome-positive or BCR::ABL1-positive B-ALL.\n3. Written informed consent of the parents or other legally authorized guardian of the patient according to local law and regulations.\n\nExclusion Criteria:\n\nShould be excluded if had any item below:\n\n1. ALL evolved from CML.\n2. Known underlying congenital immunodeficiency or metabolic disease.\n3. Congenital heart disease with cardiac insufficiency.\n4. Gastrointestinal dysfunction or gastrointestinal diseases that may significantly alter the absorption of study drug.\n5. Severe malnutrition, uncontrolled active infections, or serious cardiovascular diseases.\n6. Subjects with significant CNS disorder (e.g., uncontrolled seizure disorder, autoimmune disease involving CNS).\n7. Treated with glucocorticoids for ≥14 days, or targeted inhibitor for \\> 7 days within one month before enrollment, or any chemotherapy or any systemic anticancer therapy (including but not limited to any TKI) or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression).\n8. Any significant comorbidities or psychiatric disorders that may impact patient safety, compliance, informed consent, study participation, follow-up, or the interpretation of study results. In such cases, all participating sites must report directly to the PI to determine whether the patient meets exclusion criteria.","ALL","1 Month","18 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This prospective clinical trial evaluates the effectiveness and safety of \"chemotherapy-light\" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3\u002FCD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric\u002Fadolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol",[28,29],"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)","Childhood Leukemia, Acute Lymphoblastic",[31,32,33],"olverembatinib","Blinatumomab","venetoclax","RECRUITING","2025-08-28",{"date":37,"type":38},"2025-09-03","ACTUAL",{"date":40,"type":38},"2025-03-28",{"date":42,"type":22},"2030-06",{"name":44,"class":45},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",24,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100583878","phase-2-newly-diagnosed-low-risk-pediatric-b-cell-all-protocol-100583878","NCT06882057","Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol","Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed Low Risk Childhood B-cell Acute Lymphoblastic Leukemia","CCCG-LR-B-ALL","Inclusion Criteria:\n\nMust meet all items below:\n\n1. Age older than 1 year and younger than 18 years.\n2. Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.\n3. Diagnosis of B-ALL by immunophenotyping.\n4. Low risk group\n\nExclusion Criteria:\n\nShould be excluded in the presence of any item below:\n\n1. T-ALL\n2. I\u002FHR B-ALL group\n3. sIgM+\n4. Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.\n5. Philadelphia chromosome positive ALL (Ph-ALL)\n6. ALL evolved from chronic myeloid leukemia (CML).\n7. Down's syndrome, or major congenital or hereditary disease with organ dysfunction\n8. Secondary leukemia\n9. Known underlying congenital immunodeficiency or metabolic disease\n10. Congenital heart disease with cardiac insufficiency.\n11. Glucocorticoid treatment for ≥14 days, or ABL kinase inhibitors for \\> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)","1 Year",{"count":57,"type":22},3000,[59,25],"PHASE2","CCCG-ALL2025 LR-B-ALL plan is designed based on the CCCG-ALL2020 plan. This is a clinical trial using 14 days of blinatumomab (Blina-14) as early intensification after induction therapy and 2nd Blina-14 in consolidation therapy in all newly diagnosed provisional low-risk (LR) pediatric acute lymphoblastic leukemia (ALL) patients, regardless of measurable residual diseases (MRD) status. We will compare the efficacy of chemotherapy combined with Blina-14, comparing to CAT+ intensification or historical regimens. Patients with early remission in depth will receive chemo-light late intensification and maintenance therapy afterwards. Early complete remission in depth and maintenance reduction will be determined by next-generation sequencing (Ig-NGS MRD).",[62,29,63],"Acute Lymphoblastic Leukemia ALL","B Cell Acute Lymphoblastic Leukemia (B-ALL)",[65,66],"blinatumomab","chemo-light","2025-08-23",{"date":69,"type":38},"2025-08-26",{"date":71,"type":38},"2025-03-03",{"date":73,"type":22},"2033-06",{"name":44,"class":45},27,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":75},"100581861","phase-2-newly-diagnosed-pediatric-t-cell-all-protocol-100581861","NCT06855810","Newly-diagnosed Pediatric T-cell ALL Protocol","Chinese Children's Cancer Group T-cell Acute Lymphoblastic Leukemia -2025 Project","CCCG-TALL-2025","Inclusion Criteria:\n\n1. Age older than 1 month to younger than 18 years.\n2. Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.\n3. Diagnosis of T-ALL by immunophenotyping.\n\nExclusion Criteria:\n\n1. B-ALL\n2. AML\n3. Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.\n4. ALL evolved from chronic myeloid leukemia (CML).\n5. Down's syndrome, or major congenital or hereditary disease with organ dysfunction\n6. Secondary leukemia\n7. Known underlying congenital immunodeficiency or metabolic disease\n8. Congenital heart disease with cardiac insufficiency.\n9. Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \\> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)\n10. Any significant comorbidities or psychiatric disorders that may impact patient safety, compliance, informed consent, study participation, follow-up, or the interpretation of study results. In such cases, all participating sites must report directly to the PI to determine whether the patient meets exclusion criteria.\n11. Severe malnutrition, active infections, heart failure, or chemotherapy intolerance.",{"count":85,"type":22},610,[59,25],"This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve the minimal residual disease (MRD)-negative remission rate, enhance event-free survival (EFS), and reduce the cumulative incidence of relapse (CIR) in pediatric patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL).",[89,29,90],"Acute Lymphoblastic Leukemia","T Cell Acute Lymphoblastic Leukemia\u002FLymphoblastic Lymphoma",[92,33,93],"dasatinib","homoharringtonine",{"date":69,"type":38},{"date":96,"type":38},"2025-03-11",{"date":98,"type":22},"2031-06",{"name":44,"class":45},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":122},"100574819","phase-2-newly-diagnosed-intermediatehigh-risk-pediatric-b-cell-all-protocol-100574819","NCT06764238","Newly-diagnosed Intermediate\u002FHigh Risk Pediatric B-cell ALL Protocol","Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed for Intermediate\u002FHigh Risk Childhood B-cell ALL","CCCG-I\u002FHR-ALL","Inclusion Criteria:\n\n1. Age older than 1 month to younger than 18 years.\n2. Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.\n3. Diagnosis of B-ALL by immunophenotyping.\n\nExclusion Criteria:\n\n1. Low-risk ALL\n2. sIgM+\n3. Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.\n4. ALL evolved from chronic myeloid leukemia (CML).\n5. Down's syndrome, or major congenital or hereditary disease with organ dysfunction\n6. Secondary leukemia\n7. Known underlying congenital immunodeficiency or metabolic disease\n8. Congenital heart disease with cardiac insufficiency.\n9. Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \\> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)",{"count":109,"type":22},1800,[59,25],"Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I\u002FHR-B-ALL is thus developed to further improve the event-free survival (EFS), and overall survival (OS), and quality of life (QoL) of children with intermediate- and high- risk B-cell childhood acute lymphoblastic leukaemia (I\u002FHR-B-ALL), while decreasing adverse reactions and transplantation rates. This trial primarily aims to explore:\n\n1. The efficacy of two randomized Blinatumomab application scheme on I\u002FHR-ALL as determined by MRD negatvitiy rate.\n2. The efficacy of modified mini-hyperCVD + Venetoclax in I\u002FHR-ALL cannot afford blinatumomab, in contrast to historical control as determined by MRD negatvitiy rate.",[62,29,63],[114,33],"blinatimomab","2025-02-04",{"date":117,"type":38},"2025-02-07",{"date":119,"type":38},"2025-01-03",{"date":98,"type":22},{"name":44,"class":45},26]